在维持治疗中加入鲁比丁可改善ES-SCLC的预后

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-06-12 DOI:10.1038/s41571-025-01043-9

Diana Romero

{"title":"在维持治疗中加入鲁比丁可改善ES-SCLC的预后","authors":"Diana Romero","doi":"10.1038/s41571-025-01043-9","DOIUrl":null,"url":null,"abstract":"Patients with extensive-stage small cell lung cancer (ES-SCLC) typically receive first-line combinations of immune-checkpoint inhibitors (ICIs) and platinum-based chemotherapy followed by maintenance ICIs to limit the risk of disease progression. Now, results from the phase III IMforte trial demonstrate that the addition of lurbinectedin to maintenance therapy improves patient outcomes.A total of 660 patients with an ongoing response or stable disease after first-line therapy were randomly allocated (1:1) to receive maintenance therapy with atezolizumab with or without lurbinectedin. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"151 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-025-01043-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients with extensive-stage small cell lung cancer (ES-SCLC) typically receive first-line combinations of immune-checkpoint inhibitors (ICIs) and platinum-based chemotherapy followed by maintenance ICIs to limit the risk of disease progression. Now, results from the phase III IMforte trial demonstrate that the addition of lurbinectedin to maintenance therapy improves patient outcomes.A total of 660 patients with an ongoing response or stable disease after first-line therapy were randomly allocated (1:1) to receive maintenance therapy with atezolizumab with or without lurbinectedin. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"151 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01043-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01043-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

广泛期小细胞肺癌（ES-SCLC）患者通常接受免疫检查点抑制剂（ICIs）和铂基化疗的一线联合治疗，然后进行维持性ICIs，以限制疾病进展的风险。现在，来自IMforte III期试验的结果表明，在维持治疗中加入鲁比粘连素可以改善患者的预后。在一线治疗后，共有660例持续缓解或病情稳定的患者被随机分配（1:1）接受atezolizumab加或不加鲁比奈汀的维持治疗。无进展生存期（PFS）和总生存期（OS）是共同的主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC

Patients with extensive-stage small cell lung cancer (ES-SCLC) typically receive first-line combinations of immune-checkpoint inhibitors (ICIs) and platinum-based chemotherapy followed by maintenance ICIs to limit the risk of disease progression. Now, results from the phase III IMforte trial demonstrate that the addition of lurbinectedin to maintenance therapy improves patient outcomes.

A total of 660 patients with an ongoing response or stable disease after first-line therapy were randomly allocated (1:1) to receive maintenance therapy with atezolizumab with or without lurbinectedin. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.